NASDAQ:VCYTVeracyte Stock Price, Forecast & News

$26.05

+0.95 (+3.78 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$25.50

Now: $26.05▼

$26.60

50-Day Range

$22.13

MA: $25.32▼

$28.11

52-Week Range

$13.90

Now: $26.05▼

$31.18

Volume428,636 shs

Average Volume429,183 shs

Market Capitalization$1.30 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.83

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson, LLC and Johnson & Johnson's Lung Cancer Initiative to advance diagnostics of a nasal swab test for early lung cancer detection; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and an agreement with Johnson & Johnson Services, Inc. for the development and commercialization of novel diagnostic tests to detect lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Beat the Market (BTM) Rank^™

2.5 Analyst's Opinion

Consensus Rating
Veracyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $32.33, Veracyte has a potential upside of 24.1% from its current price of $26.05.
Amount of Analyst Coverage
Veracyte has only been the subject of 2 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
Veracyte has received 368 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Veracyte has received 240 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Veracyte has received 60.53% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote “Outperform” if you believe VCYT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Veracyte does not currently pay a dividend.
Dividend Growth
Veracyte does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,037,000.00 in company stock.
Percentage Held by Insiders
Only 8.30% of the stock of Veracyte is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Veracyte are expected to grow in the coming year, from ($0.68) to ($0.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Veracyte is -56.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Veracyte is -56.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Veracyte has a P/B Ratio of 5.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.23 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Medical laboratories

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:VCYT

Previous Symbol

CUSIPN/A

CIK1384101

Webwww.veracyte.com

Phone650-243-6300

Debt

Debt-to-Equity RatioN/A

Current Ratio9.45

Quick Ratio9.13

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$120.37 million

Price / Sales10.83

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.90 per share

Price / Book5.32

Profitability

EPS (Most Recent Fiscal Year)($0.27)

Net Income$-12,600,000.00

Net Margins-18.36%

Return on Equity-9.68%

Return on Assets-8.49%

Miscellaneous

Employees270

Outstanding Shares50,050,000

Market Cap$1.30 billion

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive VCYT News and Ratings via Email

Sign-up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.

Veracyte (NASDAQ:VCYT) Frequently Asked Questions

How has Veracyte's stock been impacted by COVID-19 (Coronavirus)?

Veracyte's stock was trading at $23.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VCYT shares have increased by 10.6% and is now trading at $26.05. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Veracyte?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veracyte.

When is Veracyte's next earnings date?

Veracyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Veracyte.

How were Veracyte's earnings last quarter?

Veracyte Inc (NASDAQ:VCYT) issued its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.18) by $0.06. The biotechnology company earned $31.12 million during the quarter, compared to the consensus estimate of $30.31 million. Veracyte had a negative net margin of 18.36% and a negative return on equity of 9.68%. View Veracyte's earnings history.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte issued an update on its first quarter 2020 After-Hours earnings guidance on Thursday, April, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $30.5-31.5 million, compared to the consensus revenue estimate of $30.35 million.

What price target have analysts set for VCYT?

3 equities research analysts have issued 12-month price objectives for Veracyte's stock. Their forecasts range from $30.00 to $35.00. On average, they anticipate Veracyte's stock price to reach $32.33 in the next year. This suggests a possible upside of 24.1% from the stock's current price. View analysts' price targets for Veracyte.

Has Veracyte been receiving favorable news coverage?

Media stories about VCYT stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Veracyte earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock's share price in the near future. View the latest news aboutVeracyte.

Who are some of Veracyte's key competitors?

Some companies that are related to Veracyte include ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Fulgent Genetics (FLGT), Centogene (CNTG), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Anpac Bio-Medical Science (ANPC), Biocept (BIOC) and Miragen Therapeutics (MGEN). View all competitors.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), CA (CA), Crispr Therapeutics (CRSP), AbbVie (ABBV), Advanced Micro Devices (AMD), Endologix (ELGX), BlackRock (BLK), InVitae (NVTA), Gilead Sciences (GILD) and Alibaba Group (BABA).

Who are Veracyte's key executives?

Veracyte's management team includes the following people:

Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 61)
Mr. Christopher M. Hall, Pres & COO (Age 50)
Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 49)
Dr. Giulia C. Kennedy Ph.D., Chief Scientific & Medical Officer (Age 60)
Mr. Ashish Kheterpal, Chief Information Officer

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Who are Veracyte's major shareholders?

Veracyte's stock is owned by many different retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (8.91%), BlackRock Inc. (8.43%), Sumitomo Mitsui Trust Holdings Inc. (6.61%), Nikko Asset Management Americas Inc. (6.57%), Nikko Asset Management Americas Inc. (6.57%) and Invesco Ltd. (6.44%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr and Keith Kennedy. View institutional ownership trends for Veracyte.

Which institutional investors are selling Veracyte stock?

VCYT stock was sold by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Lord Abbett & CO. LLC, Nuveen Asset Management LLC, Invesco Ltd., Two Sigma Advisers LP, Acadian Asset Management LLC, Squarepoint Ops LLC, and Atom Investors LP. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, John Walter Hanna Jr, and Keith Kennedy. View insider buying and selling activity for Veracyte.

Which institutional investors are buying Veracyte stock?

VCYT stock was purchased by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, William Blair Investment Management LLC, Loomis Sayles & Co. L P, Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., GW&K Investment Management LLC, and New York State Common Retirement Fund. View insider buying and selling activity for Veracyte.

How do I buy shares of Veracyte?

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $26.05.

How big of a company is Veracyte?

Veracyte has a market capitalization of $1.30 billion and generates $120.37 million in revenue each year. The biotechnology company earns $-12,600,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Veracyte employs 270 workers across the globe.

What is Veracyte's official website?

The official website for Veracyte is www.veracyte.com.

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff